Major health insurers, including BUPA Global Insurance, have approved reimbursement in the United Kingdom for our most comprehensive theranostic solution, OncoSTRAT&GO.

BUPA Global Insurance has a specific code (7331B) for the reimbursement of our test.

A direct contract is in place between the two companies, so neither the oncologist nor the patient needs to pay for taking advantage of the benefits of cancer precision medicine. 

For all other major UK insurance companies, there is a generic code, BC001211. Oncologists can reference this code to any insurer when requesting the test and when the insurer authorises it for a patient, it can then be reimbursed.

Insurance companies in other countries, like Spain, Chile, South Africa or Poland, are also covering totally or partially the cost of our tests. Please contact us for more information.

Did this answer your question?